CD-30 positive anaplastic large T-cell cutaneous lymphoma

Clinical trials for CD-30 positive anaplastic large T-cell cutaneous lymphoma explained in plain language.

Never miss a new study

Get alerted when new CD-30 positive anaplastic large T-cell cutaneous lymphoma trials appear

Sign up with your email to follow new studies for CD-30 positive anaplastic large T-cell cutaneous lymphoma, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Not yet finished but already full! 1

New drug shows promise for controlling rare skin cancers

Disease control Ongoing

This study tests a drug called brentuximab vedotin in 79 people with rare skin lymphomas (ALCL, mycosis fungoides, or lymphomatoid papulosis) that have a marker called CD30. The goal is to see if the drug can shrink or control the cancer. Participants receive the drug every 3 wee…

Matched conditions: CD-30 POSITIVE ANAPLASTIC LARGE T-CELL CUTANEOUS LYMPHOMA

Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control

Last updated Jul 18, 2026 00:00 UTC

CD-30 positive anaplastic large T-cell cutaneous lymphoma

Get alerted when new CD-30 positive anaplastic large T-cell cutaneous lymphoma trials appear

New drug shows promise for controlling rare skin cancers